Undetectable Transcription of cap in a Clinical AAV Vector: Implications for Preformed Capsid in Immune Responses
Open Access
- 1 January 2009
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 17 (1) , 144-152
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in miceJournal of Clinical Investigation, 2008
- Current status of gene therapy trials for Parkinson's diseaseExperimental Neurology, 2008
- Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In VivoJournal of Virology, 2007
- Cross-Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic T Cells But Does Not Render Hepatocytes Effective Cytolytic TargetsHuman Gene Therapy, 2007
- Treatment of human disease by adeno-associated viral gene transferHuman Genetics, 2006
- Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno-Associated Virus Production and Their in Vivo Persistence after Vector DeliveryMolecular Therapy, 2005
- Liver cell lines for the study of hepatocyte functions and immunological responseLiver International, 2005
- Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectorsJournal of Virology, 2004
- Factors Influencing Recombinant Adeno-Associated Virus ProductionHuman Gene Therapy, 1998